Free tool
FAERS Monitor: Sohonos
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 215559 or its brand name (Sohonos, Palovarotene). Reports on generic versions are filed under their own applications.
Reports
71
Serious
38
54% of reports
Hospitalization
9
Death reported
2
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- condition aggravated33
- off label use17
- dry skin14
- product dose omission issue14
- fibrodysplasia ossificans progressiva10
- pruritus10
- skin exfoliation10
- alopecia6
- rash6
- drug ineffective5
- cross sensitivity reaction4
- dyspepsia3
- fall3
- nausea3
- pain3
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2022 | 3 |
| 2023 | 3 |
| 2024 | 17 |
| 2025 | 22 |
| 2026 | 26 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,088 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| fibrodysplasia ossificans progressivaSignal | 10 | 211811.8 | 97342.2 | 1,115,090 |
| cross sensitivity reactionSignal | 4 | 1222.8 | 471.0 | 3,723 |
| skin exfoliationSignal | 10 | 35.1 | 19.8 | 299 |
| condition aggravatedSignal | 33 | 32.2 | 25.1 | 979 |
| dry skinSignal | 14 | 31.1 | 19.4 | 380 |
| product dose omission issueSignal | 14 | 14.1 | 8.8 | 160 |
| alopeciaSignal | 6 | 9.1 | 4.2 | 36 |
| dyspepsiaSignal | 3 | 9.0 | 3.0 | 14 |
| pruritusSignal | 10 | 7.7 | 4.3 | 53 |
| off label useSignal | 17 | 5.8 | 3.8 | 65 |
| rashSignal | 6 | 4.1 | 1.9 | 11 |
| fall | 3 | 2.7 | 0.9 | 2 |
| pain | 3 | 1.4 | 0.5 | 0 |
| drug ineffective | 5 | 1.1 | 0.5 | 0 |
| nausea | 3 | 1.1 | 0.4 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.